Treating neuropathic pain with neuropeptide FF receptor 2 agonists
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A receptor agonist, receptor technology, applied in the field of compounds that selectively interact with this receptor subtype, can solve the problems of onset and inefficiency in all patients
Inactive Publication Date: 2006-12-06
ACADIA PHARMA INC
View PDF3 Cites 10 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
However, existing treatments for neuralgia are not designed for these types of pain, so it is not surprising that these drugs are ineffective and do not work in all patients
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0255] Example 1: 1-(4-fluorobenzylideneamino)guanidine hydrochloride (2001)
[0256] Application of 4-fluorobenzaldehyde (5.0 mmol, 621 mg) gave the title compound (2001 ) (534 mg, 49%) as a white powder according to GP1. 1 H NMR (CD 3 OD) δ8.13(s, 1H), 7.85(m, 2H), 7.17(m, 2H); HPLC-MS (ammonium acetate) [M+H]+ = 181.1.
Embodiment 2
[0257] Example 2: 1-[(trifluoromethyl)benzylideneamino]guanidine hydrochloride (2002)
[0258] Application of 3-(trifluoromethyl)benzaldehyde (5.0 mmol, 871 mg) gave the title compound (2002) (643 mg, 48%) as a white powder according to GP1. 1 H NMR (CD 3 OD) δ8.22(s, 1H), 8.17(m, 1H), 8.05(m, 1H), 7.74(m, 1H), 7.65(m, 1H); HPLC-MS (ammonium acetate) [M+H ] + = 231.1.
Embodiment 3
[0259] Example 3: 1-[1-(3-bromophenyl)ethylideneamino]guanidine hydrochloride (2003)
[0260] According to GP1, the title compound (2003) (977 mg, 67%) was obtained as a white powder using 3'-bromoacetophenone (5.0 mmol, 995 mg). 1 H NMR (CD 3 OD) δ8.12 (ap.t, J=1.7Hz, 1H), 7.84 (ddd, J=8.0, 1.7, 1.0Hz, 1H), 7.59 (ddd, J=7.8, 2.0, 1.0Hz, 1H), 7.35(ap.t, J=8.0Hz, 1H), 2.36(s, 3H); HPLC-MS (ammonium acetate) [M+H] + = 255.1, 257.1.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
The invention described below relates to the discovery of the neuropeptide FF receptor subtype that mediates acute nociception and chronic neuropathic pain, compounds that selectively interact with this receptor subtype and methods for treating acute pain and chronic neuropathic pain.
Description
[0001] related application [0002] This application claims priority to U.S. Provisional Application No. 60 / 506,130, filed September 25, 2003, by Scully et al., entitled "Treatment of Neuralgia with Neuropeptide FF Receptor 2 Agonists," and Scully et al., 2003 Priority to U.S. Provisional Application No. 60 / 508,008, entitled "Treatment of Neuralgia with Neuropeptide FF Receptor 2 Agonists," filed October 2, 2010, which is incorporated herein by reference in its entirety, including all drawings. field of invention [0003] Aspects of the invention described below relate to methods of treating acute pain and chronic neuralgia using compounds that modulate the activity of neuropeptide FF receptor subtypes that mediate acute nociception and chronic neuralgia. Aspects of the invention also relate to compounds that selectively interact with such receptor subtypes and methods of identifying said compounds. Background of the invention [0004] Pain is a common human experience. It...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more